Recombinant CDKN2A/p14ARF Monoklonale antilichamen

Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression.

CDKN2A/p14ARF

Q8N726

Human

Recombinant human CDKN2A/p14ARF fragment

CDKN; CDKN2; MLM; CDKN2A

A318

Unconjugated

WB; IHC; IF; IP

Cell Biology; Epigenetics and Nuclear Signaling; Cancer

Protein A purified

1 mg/mL

WB 1:500-1:2000; IHC 1:200-1:1000; IF 1:50; IP 1:50-1:100

PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant.

Ice bag

Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles.

https://789.bio/eb/th5WSRkn

14 kDa

14 kDa

IgG, κ